Bavaria Joseph E, Appoo Jehangir J, Makaroun Michel S, Verter Joel, Yu Zi-Fan, Mitchell R Scott
Division of Cardiothoracic Surgery, Hospital of the Unversity of Pennsylvania Philadelphia, Pa 19104, USA.
J Thorac Cardiovasc Surg. 2007 Feb;133(2):369-77. doi: 10.1016/j.jtcvs.2006.07.040. Epub 2007 Jan 8.
Results are presented from the first completed multicenter trial directed at gaining approval from the US Food and Drug Administration of endovascular versus open surgical repair of descending thoracic aortic aneurysms.
Between September 1999 and May 2001, 140 patients with descending thoracic aneurysms were enrolled at 17 sites and evaluated for a Gore TAG Thoracic Endograft. An open surgical control cohort of 94 patients was identified by enrolling historical and concurrent subjects. Patients were assessed before treatment, at treatment, and at hospital discharge and returned for follow-up visits at 1 month, 6 months, and annually thereafter.
One hundred thirty-seven of 140 patients had successful implantation of the endograft. Perioperative mortality in the endograft versus open surgical control cohort was 2.1% (n = 3) versus 11.7% (n = 11, P < .001). Thirty-day analysis revealed a statistically significant lower incidence of the following complications in the endovascular cohort versus the surgical cohort: spinal cord ischemia (3% vs 14%), respiratory failure (4% vs 20%), and renal insufficiency (1% vs 13%). The endovascular group had a higher incidence of peripheral vascular complications (14% vs 4%). The mean lengths of intensive care unit stay (2.6 +/- 14.6 vs 5.2 +/- 7.2 days) and hospital stay (7.4 +/- 17.7 vs 14.4 +/- 12.8 days) were significantly shorter in the endovascular cohort. At 1 and 2 years' follow-up, the incidence of endoleaks was 6% and 9%, respectively. Through 2 years of follow-up, there were 3 reinterventions in the endograft cohort and none in the open surgical control cohort. Kaplan-Meier analysis revealed no difference in overall mortality at 2 years.
In this multicenter study early outcomes with descending aortic endovascular stent grafting were very encouraging when compared with those of a well-matched surgical cohort. However, at 2 years' follow-up, there is an incidence of endoleaks and reinterventions associated with endovascular versus open surgical repair. Continued vigilant surveillance of patients treated with an endograft is important.
本文展示了第一项完成的多中心试验的结果,该试验旨在获得美国食品药品监督管理局对降主动脉瘤血管内修复术与开放手术修复术的批准。
1999年9月至2001年5月期间,17个研究点招募了140例降主动脉瘤患者,并对其进行戈尔TAG胸主动脉内移植物评估。通过纳入历史病例和同期病例确定了94例开放手术对照组患者。在治疗前、治疗时和出院时对患者进行评估,并在1个月、6个月及之后每年进行随访。
140例患者中有137例成功植入内移植物。内移植物组与开放手术对照组的围手术期死亡率分别为2.1%(n = 3)和11.7%(n = 11,P <.001)。30天分析显示,与手术组相比,血管内治疗组以下并发症的发生率在统计学上显著更低:脊髓缺血(3%对14%)、呼吸衰竭(4%对20%)和肾功能不全(1%对13%)。血管内治疗组周围血管并发症的发生率更高(14%对4%)。血管内治疗组的重症监护病房平均住院时间(2.6±14.6天对5.2±7.2天)和住院时间(7.4±17.7天对14.4±12.8天)明显更短。在1年和2年的随访中,内漏发生率分别为6%和9%。在2年的随访期间,内移植物组有3例再次干预,开放手术对照组无再次干预。Kaplan-Meier分析显示2年时总体死亡率无差异。
在这项多中心研究中,与匹配良好的手术组相比,降主动脉血管内支架植入术的早期结果非常令人鼓舞。然而,在2年的随访中,血管内修复术与开放手术修复术相比存在内漏和再次干预的发生率。对接受内移植物治疗的患者持续进行密切监测很重要。